SCHEMBL8181354

SCHEMBL8181354

O=C(O)Cc1cn(Cc2cccc(Oc3ccccc3F)c2)c2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.62
▸ ALDH1A1 P00352 3/20 0.62
▸ MCL1 Q07820 3/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ PPARD Q03181 4/20 0.47
▸ CXCL8 P10145 1/20 0.47
▸ PPARG P37231 3/20 0.47
▸ PPARA Q07869 3/20 0.47
▸ ICMT O60725 3/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ PLA2G2A P14555 1/20 0.44
▸ CDC25A P30304 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13931513 0.93 LMNA (0.59) LMNAALDH1A1MCL1SMN1; SMN2NPSR1
SCHEMBL8180099 0.91 LMNA (0.63) LMNAALDH1A1MCL1SMN1; SMN2NPSR1
SCHEMBL8172743 0.89 LMNA (0.63) LMNAALDH1A1MCL1SMN1; SMN2NPSR1
SCHEMBL13931411 0.89 ALDH1A1 (0.56) LMNAALDH1A1MCL1SMN1; SMN2NPSR1
SCHEMBL13931023 0.88 LMNA (0.71) LMNAALDH1A1MCL1SMN1; SMN2NPSR1
SCHEMBL13931400 0.88 LMNA (0.60) LMNAALDH1A1MCL1SMN1; SMN2NPSR1
SCHEMBL8188581 0.88 ALDH1A1 (0.62) LMNAALDH1A1MCL1PPARDPPARG
SCHEMBL8165190 0.88 LMNA (0.65) LMNAALDH1A1MCL1SMN1; SMN2NPSR1
SCHEMBL8172745 0.88 LMNA (0.68) LMNAALDH1A1MCL1SMN1; SMN2NPSR1
SCHEMBL8188579 0.88 LMNA (0.64) LMNAALDH1A1MCL1SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 — — US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS LMNA 2969/4885ALDH1A1 1836/4885MCL1 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback